A. Gudgeon

1.7k total citations
21 papers, 973 citations indexed

About

A. Gudgeon is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, A. Gudgeon has authored 21 papers receiving a total of 973 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Cancer Research and 5 papers in Genetics. Recurrent topics in A. Gudgeon's work include Breast Cancer Treatment Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Global Cancer Incidence and Screening (4 papers). A. Gudgeon is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Global Cancer Incidence and Screening (4 papers). A. Gudgeon collaborates with scholars based in South Africa, Switzerland and United Kingdom. A. Gudgeon's co-authors include Geoffrey Falkson, W. R. Bezwoda, H.A. Chaudri, Ulrike Hornberger, Lawrence Panasci, G. Gardin, Myfanwy Morgan, Robert Leonard, P Dombernowsky and J Bellmunt and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and American Journal of Epidemiology.

In The Last Decade

A. Gudgeon

20 papers receiving 920 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Gudgeon South Africa 12 593 476 379 174 121 21 973
D. Serin France 15 759 1.3× 430 0.9× 375 1.0× 127 0.7× 203 1.7× 73 1.2k
Marit Holmqvist Sweden 15 329 0.6× 277 0.6× 293 0.8× 93 0.5× 112 0.9× 19 766
Anne Irene Hagen Norway 16 564 1.0× 608 1.3× 411 1.1× 93 0.5× 39 0.3× 31 1.2k
S. E. Hankinson United States 7 471 0.8× 263 0.6× 265 0.7× 158 0.9× 152 1.3× 14 864
H. Hamed United Kingdom 16 402 0.7× 330 0.7× 383 1.0× 125 0.7× 58 0.5× 36 995
N Sacks United Kingdom 18 976 1.6× 551 1.2× 792 2.1× 346 2.0× 52 0.4× 28 1.8k
Zakaria Einbeigi Sweden 18 457 0.8× 210 0.4× 372 1.0× 189 1.1× 55 0.5× 54 1.0k
Pentti J. Taskinen Finland 16 465 0.8× 319 0.7× 310 0.8× 235 1.4× 63 0.5× 35 1.3k
Lars‐Erik Rutqvist Sweden 18 788 1.3× 296 0.6× 194 0.5× 170 1.0× 33 0.3× 25 1.2k
Francesco Nuzzo Italy 15 710 1.2× 127 0.3× 351 0.9× 355 2.0× 132 1.1× 48 1.2k

Countries citing papers authored by A. Gudgeon

Since Specialization
Citations

This map shows the geographic impact of A. Gudgeon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Gudgeon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Gudgeon more than expected).

Fields of papers citing papers by A. Gudgeon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Gudgeon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Gudgeon. The network helps show where A. Gudgeon may publish in the future.

Co-authorship network of co-authors of A. Gudgeon

This figure shows the co-authorship network connecting the top 25 collaborators of A. Gudgeon. A scholar is included among the top collaborators of A. Gudgeon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Gudgeon. A. Gudgeon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
How, Peter, BJ Moran, Sigmar Stelzner, et al.. (2016). The MERCURY II Study: Prospective Validation of a Low Rectal Cancer Assessment System Using Magnetic Resonance Imaging, and Development of a Local Recurrence Risk Stratification Model. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 1 indexed citations
3.
Gudgeon, A.. (2014). Side-effects of systemic therapy for the management of breast cancer. South African Medical Journal. 104(5). 381–381. 1 indexed citations
4.
Murray, Elizabeth, I. D. Werner, G Schmitt, et al.. (2005). Neutron Versus Photon Radiotherapy for Local Control in Inoperable Breast Cancer. Strahlentherapie und Onkologie. 181(2). 77–81. 6 indexed citations
5.
Gelber, Shari, Alan S. Coates, Aron Goldhirsch, et al.. (2001). Effect of Pregnancy on Overall Survival After the Diagnosis of Early-Stage Breast Cancer. Journal of Clinical Oncology. 19(6). 1671–1675. 152 indexed citations
6.
Shapiro, S., Lynn Rosenberg, M. Timm Hoffman, et al.. (2000). Risk of Breast Cancer in Relation to the Use of Injectable Progestogen Contraceptives and Combined Estrogen/Progestogen Contraceptives. American Journal of Epidemiology. 151(4). 396–403. 67 indexed citations
7.
Colleoni, Marco, Anne O’Neill, Aron Goldhirsch, et al.. (2000). Identifying Breast Cancer Patients at High Risk for Bone Metastases. Journal of Clinical Oncology. 18(23). 3925–3935. 99 indexed citations
8.
Hoffman, M. Timm, Helen de Pinho, Diane Cooper, et al.. (2000). Breast cancer incidence and determinants of cancer stage in the Western Cape.. PubMed. 90(12). 1212–6. 22 indexed citations
9.
Lobo, Dileep N., et al.. (1999). Lateral internal sphincterotomy is not redundant in the era of glyceryl trinitrate therapy for chronic anal fissure. Journal of the Royal Society of Medicine. 92(4). 186–188. 16 indexed citations
10.
Bezwoda, W. R., A. Gudgeon, Geoffrey Falkson, J. P. Jordaan, & L. Goedhals. (1998). Fadrozole versus Megestrol Acetate: A Double-Blind Randomised Trial in Advanced Breast Cancer. Oncology. 55(5). 416–420. 13 indexed citations
11.
Dombernowsky, P, I E Smith, Geoffrey Falkson, et al.. (1998). Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.. Journal of Clinical Oncology. 16(2). 453–461. 473 indexed citations
12.
Bengtsson, Nils‐Olof, C Focan, A. Gudgeon, et al.. (1997). A phase III trial comparing vorozole (RIVIZOR™) versus aminoglutethimlde in the treatment of advanced postmenopausal breast cancer. European Journal of Cancer. 33. S148–S148. 10 indexed citations
13.
Castiglione‐Gertsch, Monica, Martin Tattersall, A Hacking, et al.. (1997). Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. European Journal of Cancer. 33(14). 2321–2325. 15 indexed citations
14.
Vorobiof, Daniel, L. Goedhals, A. Gudgeon, et al.. (1997). Phase II study of i.v navelbine (NVB) and doxorubicln (DOX) in previously untreated advanced breast cancer (ABC). European Journal of Cancer. 33. S155–S155. 3 indexed citations
15.
Bailie, Ross, Judith Katzenellenbogen, M. Timm Hoffman, et al.. (1997). A case control study of breast cancer risk and exposure to injectable progestogen contraceptives. Methods and patterns of use among controls.. PubMed. 87(3). 302–5. 5 indexed citations
16.
Marini, Giovanni, Susan Murray, Aron Goldhirsch, et al.. (1996). The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. Annals of Oncology. 7(3). 245–250. 17 indexed citations
17.
Smith, I. E., Geoffrey Falkson, Renaud Léonard, et al.. (1996). PP-8-3 Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA). European Journal of Cancer. 32. 49–49. 11 indexed citations
18.
19.
Goldhirsch, Aron, Richard D. Gelber, Monica Castiglione, et al.. (1994). Present and future projects of the international breast cancer study group. Cancer. 74(S3). 1139–1149. 15 indexed citations
20.
Hayes, Malcolm, A Hacking, A. Gudgeon, et al.. (1987). Fine-needle aspiration biopsy cytology of the breast. A review of the Groote Schuur Hospital experience.. PubMed. 72(8). 525–7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Serin Breakdown of academic impact, for papers by Marit Holmqvist Breakdown of academic impact, for papers by Anne Irene Hagen Breakdown of academic impact, for papers by S. E. Hankinson Breakdown of academic impact, for papers by H. Hamed Breakdown of academic impact, for papers by N Sacks Breakdown of academic impact, for papers by Zakaria Einbeigi Breakdown of academic impact, for papers by Pentti J. Taskinen Breakdown of academic impact, for papers by Lars‐Erik Rutqvist Breakdown of academic impact, for papers by Francesco Nuzzo
Rankless by CCL
2026